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BACKGROUND: Open heart surgeries under cardiopulmonary bypass are associated with excessive 
perioperative bleeding that often requires reoperation. Antifibrinolytics like epsilon aminocaproic acid 
and tranexamic acid are widely used to control bleeding. There are limited studies primarily showing the 
impact of these drugs on the incidence of reopening following open heart surgical procedures. The goal 
of this study was to compare incidence of reopening following open heart surgeries in patients who were 
administered either epsilon amino caproic acid or tranexamic acid for control of perioperative bleeding. 
METHODS: A prospective, randomized, controlled trial was performed among seventy-eight patients of 
either sex in the age group of 18 to 65 years scheduled for open heart surgeries under cardiopulmonary 
bypass. They were randomly allocated into three groups where group A (n=26) received epsilon 
aminocaproic acid, group B (n=26) received tranexamic acid and group C (control group, n=26) received 
intravenous 0.9% normal saline. Patients had similar anaesthetic protocols, and were monitored for 
twenty-four hours postoperatively to assess reopening rates because of excessive bleeding. 
RESULTS: Two patients in each group receiving either tranexamic acid or epsilon aminocaproic acid 
had excessive bleeding requiring reopening after surgery whereas three patients in the control group had 
undergone reopening for excessive bleeding (p>0.05). 
CONCLUSIONS: Epsilon aminocaproic acid and tranexamic acid exhibit similar and comparable effect 
to placebo on incidence of reopening for excessive bleeding following open heart surgeries under 
cardiopulmonary bypass 
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Open heart surgeries involving cardiopulmonary 
bypass (CPB) are associated with increased life 
threatening perioperative bleeding that may lead to 
increased morbidity, mortality, reoperation and 
administration of excessive blood products (1-3). 
Apart from surgery itself, different causes of such 
bleeding include fibrinolysis (4, 5) hemodilution 
(6, 7), and others. Antifibrinolytic agents like 
epsilon aminocaproic acid (EACA) and 
tranexamic acid (TXA) have been used to reduce 
bleeding. Studies comparing the efficacy of 
EACA and TXA in controlling postoperative 
bleeding reveal inconclusive results (8-11). 
Moreover, only limited studies are available to 
show the impact of these two antifibrinolytics on 
reoperation due to excessive bleeding (12, 13). 
This prospective and comparative study was 
conducted to find out the relative efficacy of 
EACA and TXA on post-bypass bleeding 
affecting the rate of surgical reopening in patients 
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MATERIALS AND METHODS   
 
After duly approved by the Institutional Ethics 
Committee (Trial Registration Code: Inst /IEC/ 
977/ dated 07.01.2011), this study was carried out 
in the Cardiothoracic & Vascular operation theatre 
complex of the Institute of Postgraduate Medical 
Education & Research (IPGME&R) in Kolkata 
under West Bengal University of Health Sciences, 
India, during the period from February 2011 to 
April 2012. Following written and informed 
consents, seventy-eight patients from either sex in 
the age group of 18 to 65 years and ASA physical 
status II-IV undergoing elective open heart 
surgeries under CPB were included in the study. 
Patients undergoing redo-cardiac surgery, with 
renal insufficiency (serum creatinine higher than 2 
mg/dl), undergoing ant platelet therapy, having 
haematological disorders or hepatic dysfunctions 
were excluded from the study. 
Patients were administered inhalational 
general anaesthetics (nitrous oxide, isoflurane) 
following induction with thiopentone and 
anaesthesia was maintained with positive pressure 
ventilation through endotracheal tube with the aid 
of non-depolarizing neuromuscular blockade. 
Fentanyl was used as analgesic. Various 
demographic as well as preoperative physiological 
and laboratory parameters were recorded for each 
patient. Before initiation of bypass, N2O had been 
withdrawn from inhalational anaesthetics. 
Enrolled patients were assigned randomly either to 
group A (EACA group, n=26), B (TXA group, 
n=26) and C (control group, n=26) using random 
number generators designed in Micro Soft Excel. 
Patients in Group A received an intravenous 
50ml of diluted EACA as a loading dose of 100 
mg/kg body weight before the skin incision, 
followed by a continuous infusion of 100ml of 
diluted EACA at an infusion rate of 10mg/kg/ 
hour up to 6 hours postoperatively. Group B 
received an intravenous 50ml of diluted TXA as a 
loading dose of 10mg/kg body weight before the 
skin incision, followed by a continuous infusion of 
100 ml of diluted TXA at an infusion rate of 
1mg/kg/ hour up to 6 hours postoperatively. 
Dilution of the drug was done with 0.9% normal 
saline (NS) in both the groups. Patients in Group 
C received an intravenous 50 ml of 0.9% NS as 
loading dose before the skin incision, followed by 
a continuous infusion of 100 ml of 0.9% NS up to 
6 hours postoperatively. 





C) was achieved and heparin (300U/kg) 
intravenously was administered before initiation 
of CPB. During CPB, activated clotting time 
(ACT) was maintained higher than 600 seconds. 
Following completion of surgery, patients were 
weaned off CPB, and heparin was reversed with 
intravenous protamine sulphate at dose of 1.3mg/ 
100U heparin. Off bypass, following parameters 
were checked and corrected whenever required: 1) 
patients’ core body, 2) arterial blood gases (ABG), 
3) post CPB coagulation screen: a) platelet Count 
b) international normalised ratio (INR) c) 
activated partial thromboplastin time (aPTT) and 
d) serum fibrinogen levels. Bleeding was defined 
as excessive if it was greater than 200ml/hour in 
the first four hours (14). Off bypass, all patients’ 
temperature was raised above 370C. In case of 
excessive drainage. the following institutional 
protocol was followed: ACT was rechecked and if 
found beyond 120 seconds (15), additional 
protamine sulphate was given. In case of persistent 
bleeding after correction of ACT with protamine 
sulphate, platelet count, INR, aPTT and serum 
fibrinogen levels were re-determined. Platelet 
count less than 100,000/cu mm was corrected 
platelets at the dose of  0.1µ/kg (16). Patients with 
prolonged prothrombin time (more than 1.5 times 
normal) were given fresh frozen plasma (FFP) at 
the dose of 10 ml/kg for correction (16). Serum 
fibrinogen level less than 100mg/dl was corrected 
with cryoprecipitate at the dose of 0.25µ/kg (16). 
Hematocrit less than 25% was corrected with 
packed red blood cells (PRBC) transfusion to 
maintain at 30%. 
In case of persistent bleeding even after the 
above corrective measures, a thromboelastogram 
was performed to determine abnormalities in clot 
formation and fibrinolysis, if any, and corrective 
interventions were applied depending on the 
results. Patients were monitored for twenty-four 
hours postoperatively to assess reopening rate for 
the management of excessive bleeding. 
At any point of time, if a surgically 
correctable bleed was suspected, the patient was 
taken for emergency re-exploration and dropped 
from the study. If no surgically correctable 
bleeding was detected on re-exploration, it was 
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marked as a case of excessive post CPB bleeding 
due to coagulation disorder.  
Statistical analyses: Sample size was calculated 
on the basis of total blood loss in 24 hours period 
following bypass surgery. It was estimated that 26 
subjects would be required per group in order to 
detect a difference of 200ml in blood loss between 
groups with 80% power and 5% probability of 
type-I error (17). Numerical variables of data were 
compared between groups by one way analysis of 
variance followed by Bonferroni’s test as post-hoc 
test to establish any difference between the 
groups. Categorical data were compared between 
groups by Chi-Square test or Fisher’s exact test as 
appropriate. All analyses were two-tailed and p 






All the seventy-eight patients fulfilled the 
inclusion criteria for data collection. They had 
comparable demographic profiles; there were no 
significant differences in parameters related to 
time of aortic cross clamping (AxCl) and CPB 
among the groups (Table 1). Preoperative (Table 
2) and postoperative (Table 3) coagulation profiles 
(platelet count, INR, activated partial 
thromboplastin time, serum fibrinogen levels and 
ACT) were also comparable among the groups. 
         
Table 1: Comparison of demographic profile, types of surgeries and AxCl and CPB times 
 
Parameters Gr A (n=26) Gr B (n=26) Gr C (n=26) p value 
Age (yrs) [Mean+/-SD] 33.08 ± 11.27 35.58 ± 12.07 39.04 ± 13.15 > 0.05 
Body weight (KGs) [Mean+/-SD] 52.81 ± 9.72 48.62 ± 8.07 51.27 ± 4.04 > 0.05 
Height (CMs) [Mean+/-SD] 159.58 ± 7.79 158.5 ± 8.84 156.46 ± 7.73 > 0.05 
Sex (M:F) 15 : 11 14 : 12 14 : 12 > 0.05 
Types of surgeries (ASD:AVR:MVR) 9 : 5 : 12 4: 8 : 14 6 : 7 :13 > 0.05 
AxCl time (Sec) [Mean+/-SD] 44.96 ± 17.14 48.88 ± 11.04 48.73 ± 12.3 > 0.05 
CPB time (Sec) [Mean+/-SD] 72.27 ± 17.72 74.5 ± 7.06 76.23 ± 12.61 > 0.05 
* ASD : Atrial septal defect, AVR : Aortic valve replacement, MVR : Mitral valve replacement. 
 











Table 3: Comparison of postoperative coagulation profiles of the patients. 
 
Parameters (Mean +/-SD) Gr A (n=26) Gr B (n=26) Gr C (n=26) p value 
     
Platelet (lakh/mm
3
) 2.12 ± 0.82 2.28 ± 0.93 2.03 ± 1.07 > 0.05 
INR 1.14 ± 0.16 1.17 ± 0.15 1.14 ± 0.08 > 0.05 
aPTT (seconds) 30.78 ± 4.37 32.84 ± 6.56 33.95 ± 7.51 > 0.05 
Fibrinogen (mg/dl) 168.44 ± 8.81 168.83 ± 9.27 168.81 ± 8.36 > 0.05 
ACT (seconds) 114.88 ± 9.76 114.69 ± 8.86 119.27 ± 8.48 > 0.05 
 
Parameters (Mean +/-SD) Gr A (n=26) Gr B (n=26) Gr C (n=26) p value  
Preop platelet (lakh/mm
3
) 2.55 ± 0.88 2.61 ± 0.77 2.62 ± 0.85 > 0.05  
INR 1.07 ± 0.12 1.11 ± 0.10 1.11 ± 0.11 > 0.05  
APTT (sec) 29.9 ± 4.06 30.6 ± 3.98 30.53 ± 3.92 > 0.05  
Fibrinogen (mg/dl) 164.9 ± 5.47 165.4 ± 5.98 165.59 ± 6.87 > 0.05  
Pre heparin ACT (sec) 108.88 ± 8.95 105.92 ± 10.78 108.5 ± 7.74 > 0.05 
 
 





Two patients each in groups receiving either 
tranexamic acid or epsilon aminocaproic acid 
(2/26) had excessive bleeding requiring reopening 
after surgery whereas it was in three patients out 
of 26 in control group. The differences among the 





Open heart surgeries under CPB are frequently 
associated with life threatening postoperative 
bleeding often requiring reopening (with its 
inherent risk of increased mortality and morbidity) 
to manage this complication (18, 19). Persistent 
bleeding following CPB depends on many factors. 
The causes of excessive bleeding include 
fibrinolysis, platelet dysfunction in the form of 
thrombocytopenia and /or functional alteration of 
platelet (20), heparin rebound (21), hypothermia 
(22) and many more. 
Fibrinolysis is one of the important factors 
that are primarily responsible for the hemostatic 
dysfunction induced by CPB (23). The CPB 
circuit contains a large surface of thrombogenic 
material (24). Thrombin activation results in 
fibrinolytic activity. Plasminogen activator 
concentrations rise during CPB, but levels of 
Plasminogen activator inhibitor-1 (PAI-1) remains 
unaltered (24). Antifibrinolytic agents reduce 
bleeding by inhibiting fibrinolytic pathway. Being 
a lysine analogue and antifibrinolytic agents bind 
competitively to the lysine binding sites on 
plasminogen and plasmin, inhibiting the 
interaction with fibrin. Thus, fibrin fails to 
degrade into fibrin degradation products. The 
proteolytic action of plasmin is also inhibited (25). 
Studies showed effectiveness of 
antifibrinolytic drugs in reducing perioperative 
bleeding and transfusion requirements (25, 26). 
However, limited trials are available to 
demonstrate the impact of these two 
antifibrinolytic agents on reopening rate (13). Our 
study reveals that administration of either TXA or 
EACA during open heart surgical procedures 
under CPB has similar outcome on reopening rate 
as compared to placebo. Chauhan et al had found 
both these antifibrinolytic agents could reduce 
reopening rates when compared to placebo 
following coronary artery bypass grafting (CABG) 
surgery under CPB (11). Unlike our study, 
patients exclusively undergoing CABG were 
included in their research work. Often, patients 
undergoing CABG are treated with preoperative 
antiplatelet medications. Studies showed that 
antiplatelet medication (aspirin) impairs secondary 
hemostasis and thrombus stability by acetylating 
fibrinogen and enhancing fibrinolysis (27, 28). 
Hence, antifibrinolytic agents may be more 
helpful in reducing bleeding in patients receiving 
antiplatelet therapy. Our patients did not receive 
pre-operative anti-platelet therapy eliminating 
source of bias from this issue. The difference in 
result in our study as compared to that of Chauhan 
et al partly may be because of anti-platelet therapy 
and partly may be CABG operation with 
unidentified factors which can be further 
established by future similarly designed studies. 
Set of our research work, profile of operating 
surgeons and  study population were  uniform in 
nature. The research was carried out in a post-
doctoral working unit with consistent team of 
surgeons working in the same set up for more than 
4 years.  Our study population made a cohort of 
surgical patients undergoing ASD/MVR/AVR 
operations and no one had undergone CABG 
surgery. Relative numbers of patients under each 
category of surgical procedures were  comparable 
(Table-1). Duration of bypass and age of patients 
undergoing surgery are factors for increased risk 
of bleeding following CPB (29, 30). Tetty et al 
have demonstrated that though duration of bypass 
increases post CPB bleeding, difference in the 
amount of bleeding following 1, 2 or 3 hour of 
bypass is clinically acceptable with no statistical 
significance (29). Duration of CPB in our study 
was comparable among the groups, since it was 
between 60 to 90 minutes which seems reasonable 
for cardiac surgical procedures (Table 1). 
Therefore, it seems that CPB time did not play any 
confounding impact on our results. Similarly, age 
of patients was also comparable among the groups 
without placing any biased impact on outcome of 
our study. Task force formed by Society of 
Cardiovasular Surgeons and Society of Cardiac 
Anesthesiologist has highlighted that advanced 
age ( >70 years) contributes to higher post  CPB 
bleeding (30).  We included patients aged upto 65 
years, and most of our patients were aged below 
50 years eliminating the impact of age on post-
bypass bleeding  in our study (Table1). 
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Klaus et al in 2011 analysed perioperative data of 
234 paediatric patients (114 patients receiving 
TXA in first five months and 120 patients 
receiving EACA in second five months) weighing 
less than 20kg, who had undergone cardiac 
surgery. They found that both TXA and EACA 
were comparable in their effect on reoperation 
(31). While assessing the amount of chest tube 
drainage following administration of TXA, Santos 
et al found their results comparable to that of 
placebo group in terms of reopening rate (12). The 
finding of our study are also similar with that of a 
recent study done by Henry et al. (13). They had 
found that both TXA and EACA could not 
decrease the risk of reoperation significantly. 
Based on evidences from existing studies and the 
findings of our study, it can be hypothesized that 
besides fibrinolysis, platelet dysfunction and other 
factors may also play a huge role in post CPB 
hemostatic defects (11-13, 31).  
We re-emphasize that our study had followed 
reasonably uniform methods and results, and thus, 
have the least possible bias from various possible 
confounding factors. However, future studies will 
definitely provide further data paving more 
avenues for critical comparison and analysis of 
our results. In conclusion, the results of our study 
show that prophylactic administration of either 
EACA or TXA during cardiac surgeries performed 
under CPB has insignificant effect on the rate of 
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